Aortic Valve Replacement With Perceval Bioprosthesis: Single-Center Experience With 617 Implants

Area of Science:

• Cardiovascular Surgery
• Bioprosthetics
• Minimally Invasive Procedures

Background:

• Aortic valve replacement (AVR) is a critical procedure for managing aortic valve disease.
• Sutureless bioprostheses offer potential advantages in AVR, including reduced procedure times and improved minimally invasive approaches.

Purpose of the Study:

• To evaluate the clinical and echocardiographic outcomes of the sutureless Perceval aortic bioprosthesis in a large patient cohort.
• To assess the safety, efficacy, and hemodynamic performance of this novel technology.

Main Methods:

• Retrospective analysis of 617 patients undergoing AVR with a Perceval bioprosthesis between March 2011 and December 2015.
• Data collection included patient demographics, operative details, concomitant procedures, and perioperative outcomes.
• Echocardiographic parameters and survival rates were assessed at a mean follow-up of 16.3 months.

Main Results:

• The 30-day mortality rate was 1.9%.
• Minimally invasive approaches were utilized in 92% of isolated AVR cases.
• Excellent hemodynamic performance was observed, with a mean transvalvular pressure gradient of 11.9 ± 5.4 mm Hg and a significant reduction in left ventricular mass.

Conclusions:

• Aortic valve replacement with the sutureless Perceval bioprosthesis demonstrates low mortality and favorable hemodynamic outcomes.
• Sutureless technology enhances the feasibility and reproducibility of minimally invasive AVR, potentially reducing operative times.